June 2013 – QPS360 Newsletter – Fourth Edition ›   Corporate QPS receives Company of the Year Award by Delaware Bioscience Association - May, 2013 QPS Austria Participates in the Graz Business Marathon 2013 - May, 2013 QPS Neurosciences Announces Partnership with PhoenixSongs Biologicals, Inc. and Launch of In Vitro Neural Toxicology Screening Program - April, 2013 OmniComm Systems’ TrialOne® Chosen by QPS for Phase I Clinic Automation - April, 2013 ›  Neuropharmacology α-Synuclein Transgenic Mouse Model for Parkinson’s Disease - May, 2013 ›   Toxicology QPS-Taiwan Implements Pristima™ Preclinical Data Collection and Management System - May, 2013 ›   Translational Medicine Pharmacogenomics is Improving Drug Development Outcome - May, 2013 QPS Full-Service Support for Global Biosimilar Product Development - May, 2013 ›   Early Stage Clinical First-in-Human Clinical Trials - QPS Provides Critical Drug Development Data Quickly, Accurately and Cost Effectively - May, 2013 Serial CSF Sampling for PK and Biomarker Analysis - April, 2013 Human Mass Balance Studies: New, Sophisticated On-Site Clinical ADME Laboratory - April, 2013 ›   Phase II - IV Clinical New Draft FDA Guidelines for Alzheimer´s Disease: Which Cognitive Testing Battery Guarantees Success? - May, 2013 Postoperative Cognitive Dysfunction (POCD) - April, 2013 Using Biomarker Analysis on Induced Sputum as a Measure of Primary Outcome in Asthma and COPD - April, 2013 Before a drug receives marketing approval and made available to patients, it has to be extensively studied in non-clinical and clinical studies to demonstrate its safety and efficacy. Understanding a drug’s disposition - its absorption, distribution, metabolism, and excretion (ADME) - in humans is critical for understanding its clinical properties.

Dear Industry Colleagues, We hope that 2013 is continuing to be a good year for all of our clients, vendors, and employees. QPS is pleased to take this opportunity to inform you about our continued growth and expansion during the second quarter of 2013.